<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>12984533
    </Internal_Number>
    <TrialID>ACTRN12622000775718
    </TrialID>
    <Last_Refreshed_on>24 April 2023
    </Last_Refreshed_on>
    <Public_title>The use of MRI guided focused ultrasound for the management of focal hand dystonia
    </Public_title>
    <Scientific_title>Evaluation of the efficacy and safety of MRI guided focused ultrasound (MRgFUS) for focal hand dystonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>St Vincent's Health Network Sydney
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220531
    </Date_registration3>
    <Date_registration>31/05/2022
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12622000775718.aspx
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>No limit
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>09/01/2023
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Non-randomised trial; Type of endpoint: Safety/efficacy;
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Australia
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: Patients will be included based on a formal diagnosis of focal hand dystonia (of either musician’s dystonia or writer’s subtype) as made by a consultant neurologist with specialisation in movement disorders. All patients must be at least 18 years of age and be willing to provide written consent to participate in the study. Patients must have tried and failed first line therapies for focal hand dystonia including hand therapy, oral medications and/or botulinum toxin injections.&#x0D;&lt;br&gt;All patients must be ambulant at the time of the procedure.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients will be excluded if any of the following criteria are fulfilled&#x0D;&lt;br&gt;•	History of ischaemic stroke or transient ischaemic event&#x0D;&lt;br&gt;•	History of stereotactic cerebral surgery&#x0D;&lt;br&gt;•	Diagnosis of unstable cardiac disease&#x0D;&lt;br&gt;•	Diagnosis of psychiatric disease&#x0D;&lt;br&gt;•	Cognitive impairment as indicated by a mini-mental state examination score of &lt; 24&#x0D;&lt;br&gt;•	Coagulopathy or on anticoagulation that cannot be withheld for the intervention&#x0D;&lt;br&gt;•	Skull density ratio of &lt;0.3&#x0D;&lt;br&gt;•	Absolute contraindication to MRI (eg: non-MR compatible pacemaker/defibrillator or other non-MR compatible device in situ).&#x0D;&lt;br&gt;•	Relative contraindication to MRI (such as severe claustrophobia) will be assessed on a case-by-case basis&#x0D;&lt;br&gt;•	Unwilling to provide written consent
    </Exclusion_Criteria>
    <Condition>focal hand dystonia; &lt;br&gt;focal hand dystonia;Neurological - Other neurological disorders
    </Condition>
    <Intervention>This trial aims to assess the efficacy and safety of MRgFUS in the treatment of focal hand dystonia. We aim to enrol 10 patients with focal hand dystonia, according to specific inclusion and exclusion criteria, and assess the benefit of MRgFUS in the treatment of this condition.&lt;br&gt;&lt;br&gt;All patients will undergo regular physical examination by a consultant neurologist and fellow with specialisation in movement disorders. Administration of standardised questionnaires, including the Arm Dystonia Disability Scale (ADDS), Michigan Health Outcome Questionnaire (MHOQ), Tubiana Musicians Dystonia Scale/Writer's Cramp Rating Scale (TMDS/WCRS), Short-Form 36 (SF-36) and pain numerical rating scale (NRS) will be administered at all visits except for the day of the procedure. Pre-procedure cognitive impairment will be screened using the mini-mental state examination (MMSE) and, similarly, pre- and post procedure depressive illness will be screened using the Beck Depression Inventory (BDI). If the participants meet all relevant inclusion, and no exclusion, criteria, a CT brain scan will be performed to measure the skull density ratio (SDR) using a low radiation dose CT scanner (at baseline only, not a treatment outcome). Further pre-procedural baseline screening will include assessment of neural pathways with MRI DTI tractography and resting state fMRI. Kinematic measures will be obtained using AMADEO upper extremity system and neurophysiological testing, using paired associative stimulation (PAS), will be used to measure cortical plasticity. The neurophysiological assessments are non-invasive (no recording needles are inserted) and the duration of neurophysiological testing is 60-90 minutes per study visit, with the patient seated comfortably in a neurophysiology laboratory with o
    </Intervention>
    <Primary_outcome>Change in Arm Dystonia Disability Scale (ADDS) [Baseline, and 1, 3, 6, and 12 months post the procedure];Change in Burke-Fahn-Marsden Scale of Dystonia[Baseline, and 1, 3, 6 and 12 months post the procedure];Tubiana Musicians Dystonia Scale (TMDS) for musicians dystonia&lt;br&gt;&lt;br&gt;OR&lt;br&gt;&lt;br&gt;Writers Cramp Rating Scale (WCRS)[Baseline, and 1, 3, 6, and 12 months post the procedure]
    </Primary_outcome>
    <Secondary_outcome>Safety using study specific questionnaire/sheet[Occurrence of any adverse events at the following timepoints:&#x0D;&lt;br&gt;Intraprocedural (day 0), day 1, 1 week, and 1, 3, 6, 12 months post procedure];Kinematic measures:&#x0D;&lt;br&gt;Finger/hand strength and velocity using the AMADEO upper extremity rehabilitation and analysis system[Baseline, and 1, 3, 6, 12 months post procedure];Upper limb function using the Purdue 9-hole peg-test[Baseline, and 1, 3, 6, and 12 months post the procedure];Upper limb function using the Michigan Hand Outcome Questionnaire (MHOQ)[Baseline, and 1, 3, 6, and 12 months post the procedure];Changes in cortical plasticity using paired associative stimuli latency and spatial specificity[Baseline, and 1, 3, and 12 months post the procedure];Changes in neural pathways using MRI diffusion tract imaging[Baseline, and 1, 3, and 12 months post the procedure];Screening for depression and low mood using the Beck Depression Inventory (BDI)[Baseline, and 1, 3, 6, and 12 months post the procedure];Quality of life using the Short-Form 36[Baseline, and 1, 3, 6, and 12 months post the procedure];Hand pain/discomfort using the Pain numerical rating scale (NRS)[Baseline, and 1, 3, 6, and 12 months post the procedure]
    </Secondary_outcome>
    <Secondary_ID>Nil known
    </Secondary_ID>
    <Source_Support>Dr Tisch Research Trust Fund/Curran Foundation/Philanthropic Donation;Dystonia Network of Australia;Brain Foundation
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>22/06/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>St Vincent's Hospital Research Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>13432983
    </Internal_Number>
    <TrialID>JPRN-jRCTs032210506
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Focused ultrasound pallidothalamic tractotomy for cervical dystonia
    </Public_title>
    <Scientific_title>A pilot trial of safety and effectiveness of Magnetic Resonance-guided
Focused Ultrasound (MRgFUS) Ablation of the pallidothalamic tract for the
Treatment of Cervical Dystonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Shiro Horisawa
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211222
    </Date_registration3>
    <Date_registration>22/12/2021
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCTs032210506
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 20age old
    </Inclusion_agemin>
    <Inclusion_agemax>&lt;= 70age old
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>10/03/2022
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>single arm study, single blind, uncontrolled control, single assignment, treatment purpose
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>Horisawa
    </Contact_Firstname>
    <Contact_Lastname>Shiro
    </Contact_Lastname>
    <Contact_Address>kawadacho, 8-1, Shinjuku, Tokyo
    </Contact_Address>
    <Contact_Email>neurosurgery0222@gmail.com
    </Contact_Email>
    <Contact_Tel>+81-3-3353-8111
    </Contact_Tel>
    <Contact_Affiliation>Tokyo Women's Medical University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) cervical dystonia&lt;br&gt;2) Age: 20-70&lt;br&gt;3) Toronto Western SpasmodicTorticollis Rating Scale severity scale more than 15&lt;br&gt;4) medically and botulinum toxin injection refractory cervical dystonia&lt;br&gt;5) patient who can understand the study protocol by oneself
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) inability to stop antiplatelete or anticoagulant medications&lt;br&gt;2) inability to take MRI&lt;br&gt;3) lactating or pregnant woman&lt;br&gt;4) on hemodialysis&lt;br&gt;5) intractable hypertension ( diastolic pressure &gt; 100)&lt;br&gt;6) past history of cranial surgery&lt;br&gt;7) past history of cervical surgery&lt;br&gt;8) past history of stroke&lt;br&gt;9) past history of structural lesion in the brain&lt;br&gt;10) progressive neurodegenerative disease&lt;br&gt;11) past history of psychiatric disorders&lt;br&gt;12) Any patient that in the investigator's opinion preclude participation in this study.
    </Exclusion_Criteria>
    <Condition>cervical dystonia
    </Condition>
    <Intervention>MR-guided focused ultrasound pallidothalamic tractotomy:&lt;br&gt;hair-shaved, frame fixation, MRI/CT, on the MRI/Exablate Transcranial MRgFUS therapy table, treatment sonication with intraoperative MR thermometry&lt;br&gt;the procedure takes 60-180 minutes&lt;br&gt;postoperative MRI confirm the lesion location and complications
    </Intervention>
    <Primary_outcome>6-month postoperative Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
    </Primary_outcome>
    <Secondary_outcome>BFMDRS, BDI, BAI, AES, MMSE, Postoperative neurological deficit
    </Secondary_outcome>
    <Source_Support>The Focused Ultrasound Foundation
    </Source_Support>
    <Ethics_review_status>Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>15/10/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>kenkyu-shinsa@hosp.ncgm.go.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Certified Review Board of National Center for Global Health and Medicine
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+81-3-3202-7181
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>kenkyu-shinsa@hosp.ncgm.go.jp
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>13645043
    </Internal_Number>
    <TrialID>DRKS00023540
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Effects of MR-guided focused ultrasound subthalamotomy on non-motor and motor symptoms of Parkinson’s disease patients with motor fluctuations – a pilot study.  


    </Public_title>
    <Scientific_title>Effects of MR-guided focused ultrasound subthalamotomy on non-motor and motor symptoms of Parkinson’s disease patients with motor fluctuations – a pilot study.  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Schleswig-Holstein, Campus Kiel
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201130
    </Date_registration3>
    <Date_registration>30/11/2020
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00023540
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/12/2020
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: N/A: single arm study; Masking: Open (masking not used); Control: uncontrolled; Assignment: single; Study design purpose: treatment 
    </Study_design>
    <Phase>4
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Steffen
    </Contact_Firstname>
    <Contact_Lastname>Paschen
    </Contact_Lastname>
    <Contact_Address>Arnold-Heller-Straße 3, Haus 41
    </Contact_Address>
    <Contact_Email>steffen.paschen@uksh.de
    </Contact_Email>
    <Contact_Tel>043150023956
    </Contact_Tel>
    <Contact_Affiliation>Klinik für Neurologie, UKSH, Campus Kiel
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. diagnosis of PD according to MDS diagnosis criteria for = 4 years&lt;br&gt;2. disabling motor fluctuations despite optimized medical treatment&lt;br&gt;3. a levodopa response of = 30% in the standardized levodopa-test &lt;br&gt;4. tremor of any type
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. neurosurgical contraindications (e.g. brain atrophy, history of abnormal bleeding, cerebro-vascular and cerebro- inflammatory disease)&lt;br&gt;2. standard MRI-contraindications such as non-MRI compatible implanted metallic devices including cardiac pacemakers&lt;br&gt;3. severe depression, dementia or unstable psychiatric disease&lt;br&gt;4. general contraindications (e.g. unstable cardiac status or arterial hypertension, substance abuse)
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: unilateral MRgFUS subthalamotomy of the more affected body side
    </Intervention>
    <Primary_outcome>Effects on non-motor and motor symptoms in PD. All endpoints will be exploratory. 
    </Primary_outcome>
    <Secondary_outcome>Effects on non-motor and motor symptoms in PD. All endpoints will be exploratory (for detailed description see study protocol). 
    </Secondary_outcome>
    <Source_Support>ParkinsonFonds Deutschland gGmbH
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>10/11/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkomm@email.uni-kiel.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Medizinischen Fakultät der Christian-Albrechts-Universität zu Kiel
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-431-50014191
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkomm@email.uni-kiel.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00023540#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>12291021
    </Internal_Number>
    <TrialID>NCT04720469
    </TrialID>
    <Last_Refreshed_on>30 May 2022
    </Last_Refreshed_on>
    <Public_title>A Second Magnetic Resonance Guided Focused Ultrasound Thalamotomy for Essential Tremor
    </Public_title>
    <Scientific_title>A Safety Pilot Clinical Trial of a Second Magnetic Resonance Guided Focused Ultrasound (MRgFUS) Thalamotomy for the Management of Medication-refractory Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Sunnybrook Health Sciences Centre
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201105
    </Date_registration3>
    <Date_registration>05/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04720469
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>22 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 5, 2020
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Agessandro Abrahao, MD, MSc;Nadia Scantlebury, PhD;Nadia Scantlebury, PhD
    </Contact_Lastname>
    <Contact_Email>;nadia.scantlebury@sunnybrook.ca;nadia.scantlebury@sunnybrook.ca
    </Contact_Email>
    <Contact_Tel>;416-480-6100;416-480-6100
    </Contact_Tel>
    <Contact_Affiliation>Sunnybrook Health Sciences Centre;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Individuals aged 22 years or older;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subjects who are able and willing to give consent and able to attend all study visits&#x0D;&lt;br&gt;             and MRgFUS procedure, understanding the associated risks, benefits, and alternative&#x0D;&lt;br&gt;             treatments;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Diagnosis of ET as confirmed from clinical history and examination by a neurologist or&#x0D;&lt;br&gt;             neurosurgeon and unilateral MRgFUS thalamotomy at least 48 weeks prior;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. On a stable dose of medication for tremor for at least 4 weeks;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Medication-refractory criterion: tremor refractory to adequate trials of at least two&#x0D;&lt;br&gt;             medications, one of which should be a first line therapy of either propranolol or&#x0D;&lt;br&gt;             primidone. An adequate medication trial is defined as a therapeutic dose of each&#x0D;&lt;br&gt;             medication or the development of side effects as the medication dose is titrated;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Moderate-severe tremor severity criteria in the untreated hand: Despite medical&#x0D;&lt;br&gt;             treatment, untreated hand score of =2 points in the postural or intention component of&#x0D;&lt;br&gt;             the item 5 or 6 in the Part A of CRST, AND untreated hand score of =2 points in any&#x0D;&lt;br&gt;             one of the items 12-15 of the Part B of CRST;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Disability criterion: =2 points in any one of the Part C items 17-23 as measured by&#x0D;&lt;br&gt;             the CRST;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Able to communicate sensations during the MRgFUS treatment and to press the device&#x0D;&lt;br&gt;             STOP button.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with standard contraindications for MR imaging such as non-MRI compatible&#x0D;&lt;br&gt;             implanted metallic devices including cardiac pacemakers, size limitations, etc;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Women who are pregnant;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Gait subscore =2 points in the SARA scale;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Speech subscore =2 points in the SARA scale;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Patients with advanced kidney disease (with estimated glomerular filtration rate &lt;30&#x0D;&lt;br&gt;             mL/min/1.73m2) or on dialysis;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patients with unstable cardiac status or severe hypertension including:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Documented myocardial infarction within six months of enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Unstable angina on medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Unstable or worsening congestive heart failure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Left ventricular ejection fraction below the lower limit of normal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. History of a hemodynamically unstable cardiac arrhythmia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. Cardiac pacemaker&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               7. Severe hypertension (diastolic BP &gt; 100 on medication);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Patients exhibiting any behaviour(s) or clinical assessment consistent with ethanol or&#x0D;&lt;br&gt;             substance abuse;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patients with history of abnormal bleeding, hemorrhage, and/or coagulopathy defined as&#x0D;&lt;br&gt;             abnormal coagulation profile (platelet &lt; 100,00/µl), PT (&gt;14 sec) or PTT (&gt;36 sec),&#x0D;&lt;br&gt;             and INR &gt; 1.3;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within&#x0D;&lt;br&gt;             one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage&#x0D;&lt;br&gt;             (e.g. Avastin) within one month of focused ultrasound procedure;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Ischemic or hemorrhagic stroke within 6 months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patients with brain tumors;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Individuals who are not able or unwilling to tolerate the required prolonged&#x0D;&lt;br&gt;             stationary position during treatment (approximately 2-3 hours);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Patients who are currently participating in another clinical investigation with an&#x0D;&lt;br&gt;             active treatment arm;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Patients who have had deep brain stimulation (DBS) or a prior stereotactic ablation of&#x0D;&lt;br&gt;             the basal ganglia with GKRS or radiofrequency;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Patients who have been administered botulinum toxins into the arm for 5 months prior&#x0D;&lt;br&gt;             to baseline.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Evidence of clinically important movement disorder, such as chorea, dystonia, or&#x0D;&lt;br&gt;             parkinsonism. Anyone with the presence of parkinsonian features including&#x0D;&lt;br&gt;             bradykinesia, rigidity, or postural instability will be excluded. Subjects who exhibit&#x0D;&lt;br&gt;             only mild resting tremor but no other symptoms or signs of Parkinson's disease may be&#x0D;&lt;br&gt;             included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Symptoms and signs of increased intracranial pressure (e.g. headache, nausea,&#x0D;&lt;br&gt;             vomiting, lethargy, and papilledema);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Untreated, uncontrolled sleep apnea;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. Presence of any other neurodegenerative disease like multisystem atrophy, progressive&#x0D;&lt;br&gt;             supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Mild cognitive impairment with impairment in the domain of language as determined by&#x0D;&lt;br&gt;             screening neuropsychological battery and judged by study neuropsychologist;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. A known diagnosis of dementia of any cause;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         22. Uncontrolled major psychiatric disorder or suicidal ideation. Patients with&#x0D;&lt;br&gt;             psychiatric disorders identified on initial screening can be treated for these&#x0D;&lt;br&gt;             conditions before MRgFUS treatment and enrolled if deemed psychiatrically stable for&#x0D;&lt;br&gt;             at least three months before study entry. Any presence of psychosis will be excluded;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         23. Any illness that in the investigator's opinion preclude participation in this study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         24. Patients with a history of seizures within the past year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         25. Inability to generate a thermal thalamic lesion during the first MRgFUS procedure;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         26. Poor tolerance to the first MRgFUS procedure;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         27. Severe adverse event or moderate-severe adverse event related to the MRgFUS procedure&#x0D;&lt;br&gt;             or thalamotomy, such as clinically significant and permanent speech, language,&#x0D;&lt;br&gt;             sensory, motor or gait dysfunction.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: MRgFUS thalamotomy
    </Intervention>
    <Primary_outcome>Incidence at week 12 of new onset or significant worsening of: ataxic gait; speech impairment; cognitive impairment; contralateral weakness; patient-reported disabling sensory loss; Severe AEs related to the MRgFUS procedure.
    </Primary_outcome>
    <Secondary_outcome>Change in the tremor score (Part A and B) from baseline to 12 weeks after MRgFUS thalamotomy, adjusted for baseline scores.;Change in QUEST global score and EQ-5D from baseline to 12 weeks after MRgFUS, adjusted for baseline scores.
    </Secondary_outcome>
    <Secondary_ID>3341
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>12917981
    </Internal_Number>
    <TrialID>NCT04250376
    </TrialID>
    <Last_Refreshed_on>3 April 2023
    </Last_Refreshed_on>
    <Public_title>The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias
    </Public_title>
    <Scientific_title>The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Neurological Associates of West Los Angeles
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200129
    </Date_registration3>
    <Date_registration>29/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04250376
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>93 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 27, 2017
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Sheldon E Jordan, M.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Neurology Management Associates
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  CDR stage of at least 0.5 (mild cognitive impairment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least one pathognomic imaging biomarker of a neurodegenerative process.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive decline clearly related to an acute illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects unable to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with scalp rash or open wounds on the scalp (for example from treatment of&#x0D;&lt;br&gt;             squamous cell cancer)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Advanced terminal illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Advanced kidney, pulmonary, cardiac or liver failure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who would not be able to lay down without excessive movement in a calm&#x0D;&lt;br&gt;             environment sufficiently long enough to be able to achieve sleep&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with major depressive disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with vascular causes of dementia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Mild Cognitive Impairment;Mild Dementia;Parkinson Disease;Alzheimer Disease
    </Condition>
    <Intervention>Device: Focused Transcranial Ultrasound
    </Intervention>
    <Primary_outcome>Quick Dementia Rating Scale
    </Primary_outcome>
    <Secondary_outcome>Repeatable Battery Assessment for Neuropsychological Status (RBANS);Repeatable Battery Assessment for Neuropsychological Status (RBANS);Montreal Cognitive Assessment (MoCA);Montreal Cognitive Assessment (MoCA);Quick Dementia Rating Scale (QDRS)
    </Secondary_outcome>
    <Secondary_ID>32222-1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>13642023
    </Internal_Number>
    <TrialID>DRKS00016695
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Long-Term Tremor Evaluation In Patients Receiving Incisionless Surgery with FUS
    </Public_title>
    <Scientific_title>Long-Term Tremor Evaluation In Patients Receiving Incisionless Surgery with FUS - LOTTE in Paris with FUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Universitätsklinik Bonn: NeuroRadiologische Klinik, Radiologische Klinik, Klinik für Neurologie, Neurochirurgische Klinik Hauptverantwortliche der Studie: Prof. Dr. U. Wüllner, Prof. Dr. H. Vatter, Prof. Dr. H. Boecker, Prof. Dr. A. Radbruch
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190205
    </Date_registration3>
    <Date_registration>05/02/2019
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00016695
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/03/2019
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Ullrich
    </Contact_Firstname>
    <Contact_Lastname>Wüllner
    </Contact_Lastname>
    <Contact_Address>Sigmund-Freud-Strasse 25
    </Contact_Address>
    <Contact_Email>ullrich.wuellner@ukbonn.de
    </Contact_Email>
    <Contact_Tel>+49 (0) 228 2871 5712
    </Contact_Tel>
    <Contact_Affiliation>Sektion Bewegungsstörungen Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: both sexes, Age 18 and older, patients with a proven movement disorder of the head (tremor, dystonia) or motoric restlessness, who can tolerate the clinically established MRgFUS therapy and are suitable for it&lt;br&gt;Ability of the patient to give informed consent, MRI capability according to the safety standards defined for the study clinic
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Deviation from inclusion criteria, withdrawal of consent, patients who do not meet the criteria for a safe MRI, or who would otherwise be classified as having a high risk according to the general hospital MRI check result, patients included in the screening questionnaire have found MRI or study participation to be a burden.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G25.0 &lt;br&gt;G20.9;Essential tremor;G25.0;G20.9
    </Condition>
    <Intervention>Group 1: Procedure:&lt;br&gt;1. Study MRI with DTI, Resting State, Task-based fMRI as well as Clinical Testing and Electro-neurography before clinically indicated MRgFUS therapy&lt;br&gt;2. Study MRI with DTI, Resting State, Task-based fMRI as well as Clinical Testing and Electro-neurography immediately after therapy&lt;br&gt;3. 1-month follow-up with examinations as in 1. and 2.&lt;br&gt;4. 6-month follow-up as in 1.-3.&lt;br&gt;5. 1-year follow-up as in 1.-4.
    </Intervention>
    <Primary_outcome>Observational study without classic endpoint.&lt;br&gt;Aims:&lt;br&gt;1. Identify optimal thalamic therapy point in the brain for future MRgFUS therapies&lt;br&gt;2. to individualize the therapy to the individual patient (optimization of the therapy point, the delivered amount of energy, the point size related to the tremor shape / diagnosis)&lt;br&gt;3. Generate long-term findings regarding the outcome according to MRgFUS.
    </Primary_outcome>
    <Secondary_outcome>see above
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft INST 1172 / 64-1 FUGG
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>28/01/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethik@ukbonn.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission Medizinische Fakultät Bonn
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-228-28751282
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethik@ukbonn.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00016695#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>13432776
    </Internal_Number>
    <TrialID>JPRN-jRCTs032180081
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>PD001J
    </Public_title>
    <Scientific_title>A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease. - PD001J                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>KAMEI TETSUMASA
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190115
    </Date_registration3>
    <Date_registration>15/01/2019
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCTs032180081
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 20age old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>25/04/2017
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
    </Study_design>
    <Phase>3
    </Phase>
    <Contact_Firstname>ETSUKO
    </Contact_Firstname>
    <Contact_Lastname>SHIMIZU
    </Contact_Lastname>
    <Contact_Address>1-5-1 Kandai Tsujido Fujisawa Kanagawa Japan
    </Contact_Address>
    <Contact_Email>etsuko.shimizu@tokushukai.jp
    </Contact_Email>
    <Contact_Tel>+81-466-35-1177
    </Contact_Tel>
    <Contact_Affiliation>Medical Corporation Tokushukai Shonanfujisawa Tokushukai Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 01 Men and women, age 20 years and older. 02 Subjects who are able and willing to give informed consent and able to attend all study visits. 03 Subjects with a diagnosis of idiopathic PD as confirmed from clinical history and examination by a movement disorder neurologist at the site. 04 All subjects included in this study will have a TD/PIGD ratio &gt; 1.15 in the medicated [ON] state as calculated from the UPDRS formula as described by S, et. al., [74]. 05 Subject demonstrates a resting tremor severity score of greater than or equal to 3 in the hand/arm as measured by the medicated (ON) MDS-UPDRS question 3.17 or a postural/action tremor greater than or equal to a 2 for question 3.15 or 3.16. 06 Significant disability due to PD tremor despite medical treatment (CRST score of 2 or above in any one of the items 16-23 from the Disability subsection of the CRST: [speaking, feeding other than liquids, bringing liquids to mouth, hygiene, dressing, writing, working, and social activities.]) 07 Tremor remains disabling when medical therapy is optimal or not tolerated for the treatment of other cardinal signs of PD (bradykinesia, rigidity, etc), as determined by a movement disorders neurologist at the site. 08 Subjects should be on a stable dose of all PD medications for 30 days prior to study entry. 09 The thalamus must be apparent on MRI such that targeting of the Vim nucleus can be performed indirectly by measurement from a line connecting the anterior and posterior commissures of the brain. 10 Subject is able to communicate sensations during the ExAblate Transcranial procedure.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 01 Subjects with unstable cardiac status including: a)Unstable angina pectoris on medication. b)Subjects with documented myocardial infarction within six months of protocol entry c)Significant congestive heart failure defined with ejection fraction &lt; 40. d)Subjects with unstable ventricular arrhythmias. e)Subjects with atrial arrhythmias that are not rate-controlled. 02 Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlinnyuued in the DSM-IV as manifested by one (or more) of the following occurring within the preceding 12 month period: a)Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household). b)Recurrent substance use in situations in which it is physically hazardous.(such as driving an automobile or operating a machine when impaired by substance use) c)Recurrent substance-related legal problems.(such as arrests for substance related disorderly conduct) d)Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (for example, arguments with spouse about consequences of intoxication and physical fights). 03 Severe hypertension (diastolic BP &gt; 100 on medication.) 04 Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc. 05 Significant claustrophobia that cannot be managed with mild medication. 06 Current medical condition resulting in abnormal bleeding and/or coagulopathy. 07 Patient with severely impaired renal function with estimated glomerular filtration rate &lt;30mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis; 08 Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure. 09 Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: platelet count less than 100,000 per cubic millimeter, a documented clinical coagulopathy, or INR coagulation studies exceeding the institutions laboratory standard. 10 History of intracranial hemorrhage. 11 History of multiple strokes, or a stroke within past 6 months. 12 Subject who weigh more than the upper weight limit of the table or subjects who will not fit into the MR scanner. 13 Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment. 14 Are participating or have participated in another clinical trial in the last 30 days. 15 Subjects unable to communicate with the investigator and staff. 16 Presence of central neurodegenerative disease, including but not limited to Parkinson-plus syndromes, suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimers disease. 17 Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications. 18 Presence of significant cognitive impairment as determined with a score &lt; 24 on the MMSE(Mini-Mental State Examination ). 19 Unstable psychiatri
    </Exclusion_Criteria>
    <Condition>Medication-Refractory Tremor Dominant Idiopathic Parkinsons Disease
    </Condition>
    <Intervention>ExAblate Transcranial MRgFUS Thalamotomy Treatment
    </Intervention>
    <Primary_outcome>The primary endpoint measured will be safety of unilateral, 3Tesla, ExAblate Transcranial thalamotomy for TDPD as determined from adverse events recorded during the one year study period.
    </Primary_outcome>
    <Secondary_outcome>Secondary efficacy endpoints will include comparison of Baseline to Month 3 and Month 12 assessments for: 1)On-medication, tremor score from items 20 and 21 of the UPDRS. 2)On-medication, motor score from UPDRS, part III. 3)On-medication, total tremor (CRST) score. 4)Level of disability measured from Part C subsection of CRST. 5)Quality of life assessment with PDQ-39 and Quality of Life in Essential Tremor Questionnaire (QUEST) in this study.
    </Secondary_outcome>
    <Secondary_ID>UMIN000033940
    </Secondary_ID>
    <Source_Support>InSightec
    </Source_Support>
    <Ethics_review_status>Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>crb_itoku@shonankamakura.or.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Medical Corporation  Tokushukai Certified Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+81-3-3265-4804
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>crb_itoku@shonankamakura.or.jp
    </Ethics_review_contact_email>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>06/09/2023
    </results_date_posted>
    <results_date_completed>31/12/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>12987637
    </Internal_Number>
    <TrialID>NCT03253991
    </TrialID>
    <Last_Refreshed_on>1 May 2023
    </Last_Refreshed_on>
    <Public_title>A Study to Evaluate the Effectiveness and Safety of ExAblate MRgFUS on Essential Tremor
    </Public_title>
    <Scientific_title>A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>InSightec
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170724
    </Date_registration3>
    <Date_registration>24/07/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03253991
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>22 Years
    </Inclusion_agemin>
    <Inclusion_agemax>99 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 17, 2014
    </Date_enrollement>
    <Target_size>154
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China;Japan;Taiwan;China;Japan;Taiwan
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Men and women age 22 years or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A diagnosis of ET as confirmed from clinical history and examination by a neurologist&#x0D;&lt;br&gt;             or neurosurgeon specialized in movement disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have had an inadequate response to one or two oral doses of medication, per local&#x0D;&lt;br&gt;             standards. An inadequate medication trial is defined as a therapeutic dose of each&#x0D;&lt;br&gt;             medication and poor response to drug, or the development of side effects as the&#x0D;&lt;br&gt;             medication dose is titrated.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to communicate sensations during the ExAblate TcMRgFUS treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with unstable cardiac status&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe hypertension (diastolic BP &gt; 100 on medication)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with standard contraindications for MR imaging such as non-MRI compatible&#x0D;&lt;br&gt;             implanted metallic devices including cardiac pacemakers, size limitations, etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or&#x0D;&lt;br&gt;             Magnevist) including advanced kidney disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with severely impaired renal function&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of abnormal bleeding and/or coagulopathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of immunocompromise including those who are HIV positive.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of intracranial hemorrhage&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cerebrovascular disease (multiple CVA or CVA within 6 months)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with uncontrolled symptoms and signs of increased intracranial pressure&#x0D;&lt;br&gt;             (e.g., headache, nausea, vomiting, lethargy, papilledema).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who are not able or willing to tolerate the required prolonged stationary&#x0D;&lt;br&gt;             supine position during treatment (can be up to 4 hrs of total table time.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Are participating or have participated in another clinical trial in the last 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant claustrophobia that cannot be managed with mild medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any other neurodegenerative disease such as Parkinson-plus syndromes&#x0D;&lt;br&gt;             suspected on neurological examination.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of significant cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with life-threatening systemic disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with a history of seizures within the past year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with presence or history of psychosis&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: MRgFUS treatment
    </Intervention>
    <Primary_outcome>Safety - Will be determined evaluating incidence and severity of device related complications from first treatment day visit through all follow ups. Relative Safety will be evaluated describing Significant Clinical Complications for patients treated.;Effectiveness - Will be evaluated using the Clinical Rating Scale for Tremors (CRST) for ET subjects. Comparison will be performed from examinations at baseline and 3-Months post-ExAblate treatment.
    </Primary_outcome>
    <Secondary_ID>ET002J
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>13461063
    </Internal_Number>
    <TrialID>JPRN-UMIN000026952
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Analysis for pathological networks in the essential tremor and identification of biomarkers for MR-guided focus ultrasound therapy
    </Public_title>
    <Scientific_title>Analysis for pathological networks in the essential tremor and identification of biomarkers for MR-guided focus ultrasound therapy - Network analysis for essential tremor and effectiveness of MRgFUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Nagoya University School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170601
    </Date_registration3>
    <Date_registration>01/06/2017
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030912
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>89years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2017/06/01
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not selected
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Satoshi Maesawa
    </Contact_Lastname>
    <Contact_Address>65 Tsurumai, Showa, Nagoya
    </Contact_Address>
    <Contact_Email>smaesawa@med.nagoya-u.ac.jp
    </Contact_Email>
    <Contact_Tel>052-744-2353
    </Contact_Tel>
    <Contact_Affiliation>Nagoya University School of Medicine Brain and Mind Research Center, Neurosurgery
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: patients with congitive dysfunction  patients with any obstacles for surgical intervention including coagulation disorder or phobia of MRI
    </Exclusion_Criteria>
    <Condition>Essential tremor
    </Condition>
    <Intervention>MRgFUS treatment
    </Intervention>
    <Primary_outcome>brain network by resting state fMRI and MEG
    </Primary_outcome>
    <Source_Support>KAKENHI
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>5416646
    </Internal_Number>
    <TrialID>NCT02037217
    </TrialID>
    <Last_Refreshed_on>11 April 2016
    </Last_Refreshed_on>
    <Public_title>ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor
    </Public_title>
    <Scientific_title>A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>InSightec
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140114
    </Date_registration3>
    <Date_registration>14/01/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02037217
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>February 2011
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>Korea, Republic of
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jin Woo Chang, Prof.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Yonsei University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Men and women, between 18 and 80 years, inclusive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients who are able and willing to give consent and able to attend all study visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. A diagnosis of ET as confirmed from clinical history and examination by a movement&#x0D;&lt;br&gt;             disorder neurologist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Tremor refractory to adequate trials of at least two medications, one of which should&#x0D;&lt;br&gt;             be either propranolol or primidone. An adequate medication trial is defined as a&#x0D;&lt;br&gt;             therapeutic dose of each medication or the development of side effects as the&#x0D;&lt;br&gt;             medication dose is titrated.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Vim nucleus of thalamus can be target by the ExAblate device. The Vim region of the&#x0D;&lt;br&gt;             thalamus must be apparent on MRI such that targeting can be performed with either&#x0D;&lt;br&gt;             direct visualization or by measurement from a line connecting the anterior and&#x0D;&lt;br&gt;             posterior commissures of the brain.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Able to communicate sensations during the ExAblate MRgFUS treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Postural or intention tremor severity score of greater than or equal to 2 in the&#x0D;&lt;br&gt;             dominant hand/arm as measured by the CRST rating scale.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Stable doses of all medications for 30 days prior to study entry and for the duration&#x0D;&lt;br&gt;             of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. May have bilateral appendicular tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Significant disability due to essential tremor despite medical treatment (CRST score&#x0D;&lt;br&gt;             of 2 or above in any one of the items 16-23 from the Disability subsection of the&#x0D;&lt;br&gt;             CRST: [speaking, feeding other than liquids, bringing liquids to mouth, hygiene,&#x0D;&lt;br&gt;             dressing, writing, working, and social activities])&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Inclusion and exclusion criteria have been agreed upon by two members of the medical&#x0D;&lt;br&gt;             team.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with unstable cardiac status including:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             1.1 Unstable angina pectoris on medication 1.2 Patients with documented myocardial&#x0D;&lt;br&gt;             infarction within six months of protocol entry 1.3 Congestive heart failure requiring&#x0D;&lt;br&gt;             medication (other than diuretic) 1.4 Patients on anti-arrhythmic drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients exhibiting any behavior(s) consistent with ethanol or substance abuse as&#x0D;&lt;br&gt;             defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the&#x0D;&lt;br&gt;             following occurring within a 12 month period:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Recurrent substance use resulting in a failure to fulfill major role obligations&#x0D;&lt;br&gt;                  at work, school, or home (such as repeated absences or poor work performance&#x0D;&lt;br&gt;                  related to substance use; substance-related absences, suspensions, or expulsions&#x0D;&lt;br&gt;                  from school; or neglect of children or household).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Recurrent substance use in situations in which it is physically hazardous (such&#x0D;&lt;br&gt;                  as driving an automobile or operating a machine when impaired by substance use)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Recurrent substance-related legal problems (such as arrests for substance&#x0D;&lt;br&gt;                  related disorderly conduct)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Continued substance use despite having persistent or recurrent social or&#x0D;&lt;br&gt;                  interpersonal problems caused or exacerbated by the effects of the substance&#x0D;&lt;br&gt;                  (for example, arguments with spouse about consequences of intoxication and&#x0D;&lt;br&gt;                  physical fights).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Severe hypertension (diastolic BP &gt; 100 on medication)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with standard contraindications for MR imaging such as non-MRI compatible&#x0D;&lt;br&gt;             implanted metallic devices including cardiac pacemakers, size limitations, etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or&#x0D;&lt;br&gt;             Magnevist) including advanced kidney disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Severely impaired renal function (estimated glomerular filtration rate &lt;&#x0D;&lt;br&gt;             45ml/min/1.73 m2) or receiving dialysis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. History of abnormal bleeding and/or coagulopathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within&#x0D;&lt;br&gt;             one week of focused ultrasound procedure or drugs known to increase risk or&#x0D;&lt;br&gt;             hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Active or suspected acute or chronic uncontrolled infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. History of intracranial hemorrhage&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Cerebrovascular disease (multiple CVA or CVA within 6 months)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Individuals who are not able or willing to tolerate the required prolonged stationary&#x0D;&lt;br&gt;             supine position during treatment (can be up to 4 hrs of total table time.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Symptoms and signs of increased intracranial pressue (e.g. headache, nausea,&#x0D;&lt;br&gt;             vomiting, lethargy, and papilledema)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Are participating or have participated in another clinical trial in the last 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Patients unable to communicate with the investigator and staff.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Presence of any other neurodegenerative disease like parkinson-plus syndromes&#x0D;&lt;br&gt;             suspected on neurological examination. These include: multisystem atrophy,&#x0D;&lt;br&gt;             progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer?s disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Anyone suspected to have the diagnosis of idiopathic Parkinson?s disease. This&#x0D;&lt;br&gt;             includes excluding anyone with the presence of parkinsonian features including&#x0D;&lt;br&gt;             bradykinesia rigidity, or postural instability. Subjects who exhibit only mild&#x0D;&lt;br&gt;             resting tremor but no other symptoms or signs of PD may be included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Presence of significant cognitive impairment as determined with a score = 24 on the&#x0D;&lt;br&gt;             Mini Mental Status Examination (MMSE)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. History of immunocompromise, including patient who is HIV positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Known life-threatening systemic disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. Patients with a history of seizures within the past year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         22. Patients with current or a prior history of any psychiatric illness will be excluded.&#x0D;&lt;br&gt;             Any presence or history of psychosis will be excluded. Patients with mood disorders&#x0D;&lt;br&gt;             including depression will be excluded. For the purpose of this study, we consider a&#x0D;&lt;br&gt;             significant mood disorder to include any patient who has:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  been under the care of a psychiatrist for over 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  taken antidepressant medications for greater than 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  has participated in cognitive-behavioral therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  been hospitalized for the treatment of a psychiatric illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  received transcranial magnetic stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  received electroconvulsive therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         23. Patients with risk factors for intraoperative or postoperative bleeding (platelet&#x0D;&lt;br&gt;             count less than 100,000 per cubic millimeter, PT &gt; 14, PTT &gt; 36 or INR &gt; 1.3) or a&#x0D;&lt;br&gt;             documented coagulopathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         24. Patients with brain tumors&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         25. Any illness that in the investigator's opinion preclude participation in this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         26. Pregnancy or lactation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         27. Legal incapacity or limited legal capacity.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         28. Patients who have had deep brain stimulation or a
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: ExAblate Transcranial MRgFUS System
    </Intervention>
    <Primary_outcome>Device or procedure related Adverse Events reported
    </Primary_outcome>
    <Secondary_outcome>Tremor rating scales: the Clinical Rating Scale for Tremors
    </Secondary_outcome>
    <Secondary_ID>ET001K
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:44:29</Export_date>
    <Internal_Number>4689049
    </Internal_Number>
    <TrialID>NCT01304758
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor
    </Public_title>
    <Scientific_title>A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Essential Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>InSightec
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20110211
    </Date_registration3>
    <Date_registration>11/02/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01304758
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>January 2011
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Men and women, between 18 and 80 years, inclusive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients who are able and willing to give consent and able to attend all study visits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. A diagnosis of  ET  as confirmed from clinical history and examination by a movement&#x0D;&lt;br&gt;             disorder neurologist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Tremor refractory to adequate trials of at least two medications, one of which should&#x0D;&lt;br&gt;             be either propranolol or primidone.  An adequate medication trial is defined as a&#x0D;&lt;br&gt;             therapeutic dose of each medication or the development of side effects as the&#x0D;&lt;br&gt;             medication dose is titrated.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Vim nucleus of thalamus can be target by the ExAblate device.  The Vim/ region of the&#x0D;&lt;br&gt;             thalamus must be apparent on MRI such that targeting can be performed with either&#x0D;&lt;br&gt;             direct visualization or by measurement from a line connecting the anterior and&#x0D;&lt;br&gt;             posterior commissures of the brain.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Able to communicate sensations during the ExAblate MRgFUS treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Postural or intention tremor severity score of greater than or equal to 2 in the&#x0D;&lt;br&gt;             dominant hand/arm as measured by the CRST rating scale.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Stable doses of all medications for 30 days prior to study entry and for the duration&#x0D;&lt;br&gt;             of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. May have bilateral appendicular tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Significant disability due to essential tremor despite medical treatment CRST score&#x0D;&lt;br&gt;             of 2 or above in any one of the items 16-23 from the Disability subsection of the&#x0D;&lt;br&gt;             CRST: [speaking, feeding other than liquids, bringing liquids to mouth, hygiene,&#x0D;&lt;br&gt;             dressing, writing, working, and social activities])&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Inclusion and exclusion criteria have been agreed upon by two members of the medical&#x0D;&lt;br&gt;             team.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with unstable cardiac status including:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Unstable angina pectoris on medication Patients with documented myocardial infarction&#x0D;&lt;br&gt;             within six months of protocol entry Congestive heart failure requiring medication&#x0D;&lt;br&gt;             (other than diuretic) Patients on anti-arrhythmic drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients exhibiting any behavior(s) consistent with ethanol or substance abuse as&#x0D;&lt;br&gt;             defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the&#x0D;&lt;br&gt;             following occurring within a 12 month period: Recurrent substance use resulting in a&#x0D;&lt;br&gt;             failure to fulfill major role obligations at work, school, or home (such as repeated&#x0D;&lt;br&gt;             absences or poor work performance related to substance use; substance-related&#x0D;&lt;br&gt;             absences, suspensions, or expulsions from school; or neglect of children or&#x0D;&lt;br&gt;             household).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Recurrent substance use in situations in which it is physically hazardous (such as&#x0D;&lt;br&gt;             driving an automobile or operating a machine when impaired by substance use)&#x0D;&lt;br&gt;             Recurrent substance-related legal problems (such as arrests for substance related&#x0D;&lt;br&gt;             disorderly conduct) Continued substance use despite having persistent or recurrent&#x0D;&lt;br&gt;             social or interpersonal problems caused or exacerbated by the effects of the&#x0D;&lt;br&gt;             substance (for example, arguments with spouse about consequences of intoxication and&#x0D;&lt;br&gt;             physical fights).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Severe hypertension (diastolic BP &gt; 100 on medication)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with standard contraindications for MR imaging such as non-MRI compatible&#x0D;&lt;br&gt;             implanted metallic devices including cardiac pacemakers, size limitations, etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or&#x0D;&lt;br&gt;             Magnevist) including advanced kidney disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Severely impaired renal function (estimated glomerular filtration rate &lt;&#x0D;&lt;br&gt;             45ml/min/1.73 m2) or receiving dialysis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. History of abnormal bleeding and/or coagulopathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within&#x0D;&lt;br&gt;             one week of focused ultrasound procedure or drugs known to increase risk or&#x0D;&lt;br&gt;             hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Active or suspected acute or chronic uncontrolled infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. History of intracranial hemorrhage&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Cerebrovascular disease (multiple CVA or CVA within 6 months)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Individuals who are not able or willing to tolerate the required prolonged stationary&#x0D;&lt;br&gt;             supine position during treatment (can be up to 4 hrs of total table time.)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Symptoms and signs of increased intracranial pressure (e.g. headache, nausea,&#x0D;&lt;br&gt;             vomiting, lethargy, and papilledema)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Are participating or have participated in another clinical trial in the last 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Patients unable to communicate with the investigator and staff.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Presence of any other neurodegenerative disease like parkinson-plus syndromes&#x0D;&lt;br&gt;             suspected on neurological examination.  These include: multisystem atrophy,&#x0D;&lt;br&gt;             progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Anyone suspected to have the diagnosis of idiopathic Parkinson's disease.  This&#x0D;&lt;br&gt;             includes excluding anyone with the  presence of parkinsonian features including&#x0D;&lt;br&gt;             bradykinesia rigidity, or postural instability.  Subjects who exhibit only mild&#x0D;&lt;br&gt;             resting tremor but no other symptoms or signs of PD may be included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         18. Presence of significant cognitive impairment as determined with a score less than or&#x0D;&lt;br&gt;             equal to 24 on the Mini Mental Status Examination (MMSE)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         19. History of immunocompromise, including patient who is HIV positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         20. Known life-threatening systemic disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         21. Patients with a history of seizures within the past year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         22. Patients with current or a prior history of any psychiatric illness will be excluded.&#x0D;&lt;br&gt;              Any presence or history of psychosis will be excluded. Patients with mood disorders&#x0D;&lt;br&gt;             including depression will be excluded.  For the purpose of this study, we consider a&#x0D;&lt;br&gt;             significant mood disorder to include any patient who has: been under the care of a&#x0D;&lt;br&gt;             psychiatrist for over 3 months taken antidepressant medications for greater than 6&#x0D;&lt;br&gt;             months has participated in cognitive-behavioral therapy been hospitalized for the&#x0D;&lt;br&gt;             treatment of a psychiatric illness received transcranial magnetic stimulation&#x0D;&lt;br&gt;             received electroconvulsive therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         23. Patients with risk factors for intraoperative or postoperative bleeding (platelet&#x0D;&lt;br&gt;             count less than 100,000 per cubic millimeter, PT &gt; 14, PTT &gt; 36 or INR &gt; 1.3) or a&#x0D;&lt;br&gt;             documented coagulopathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         24. Patients with brain tumors&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         25. Any illness that in the investigator's opinion preclude participation in this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         26. Pregnancy or lactation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         27. Legal incapacity or limited legal capacity.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: ExAblate Transcranial MRgFUS System
    </Intervention>
    <Primary_outcome>Device or procedure related Adverse Events reported
    </Primary_outcome>
    <Secondary_outcome>Tremor rating scales: the Clinical Rating Scale for Tremors
    </Secondary_outcome>
    <Secondary_ID>ET001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>
</Trials_downloaded_from_ICTRP>